共 50 条
Vitamin D supplementation is a cost-effective intervention after posterolateral lumbar fusion: a systematic review
被引:0
|作者:
Patel, Dhiraj
[1
,2
]
Lippel, Matthew
[1
]
Lunardini, David
[1
]
Monsey, Robert
[1
]
Ziino, Chason
[1
]
机构:
[1] Univ Vermont, Dept Orthoped Surg, Larner Coll Med, Burlington, VT USA
[2] 149 Pine St,Apt B, Burlington, VT 05401 USA
来源:
关键词:
pseudarthrosis;
cost-effectiveness;
vitamin D deficiency;
posterolateral fusion;
SPINAL-FUSION;
GEOGRAPHIC LOCATION;
REVISION FUSION;
D DEFICIENCY;
SURGERY;
PSEUDOARTHROSIS;
OUTCOMES;
D O I:
10.1097/BCO.0000000000001188
中图分类号:
R826.8 [整形外科学];
R782.2 [口腔颌面部整形外科学];
R726.2 [小儿整形外科学];
R62 [整形外科学(修复外科学)];
学科分类号:
摘要:
Background:This study investigated the role of preoperative supplementation of 25(OH)D, a precursor of the active form of vitamin D, as a cost-effective strategy to decrease pseudarthrosis rates and overall healthcare burden after posterolateral fusion (PLF). Previous literature has emphasized the importance of vitamin D in bone health maintenance, spinal health, and outcomes in spinal fusion. Inadequate preoperative 25(OH)D levels may increase pseudarthrosis rates after PLF. Thus, a cost-estimation model was developed to determine the cost-effectiveness of both selective and nonselective 25(OH)D supplementation in PLF. Methods:Prevalence and cost data were obtained from published literature through systematic reviews. Cost of serum 25(OH)D assay and supplementation were obtained from public-use data. Mean, lower, and upper bounds of 1-year cost-savings were calculated for both supplementation scenarios. Results:Preoperative 25(OH)D screening and subsequent selective 25(OH)D supplementation was calculated to result in a mean cost-savings of $10,978,440 ($9,969,394 to $11,987,485) per 10,000 PLF cases. Nonselective 25(OH)D supplementation of all PLF patients was calculated to result in a mean cost-savings of $11,213,318 ($10,204,272 to $12,222,363) per 10,000 cases. Univariate adjustment projects that selective supplementation is a cost-effective strategy in clinical contexts where revision PLF costs exceed $781.89 and prevalence of 25(OH)D deficiency >= 0.612%. Nonselective supplementation is cost-effective in clinical scenarios where revision PLF cost >=$198.09 and prevalence of 25(OH)D deficiency >= 0.1645%. Conclusions:This cost-predictive model promotes the role of preoperative 25(OH)D supplementation as a cost-effective mechanism to reduce overall healthcare burden after PLF. Nonselective supplementation appears to be more cost-effective than selective supplementation, likely due to the relatively lower cost of 25(OH)D supplementation compared with serum assays.
引用
收藏
页码:9 / 15
页数:7
相关论文